Douglas Graham MD PhD

PubMed

• Free-floating long-term vascularized mesenchymal organoids.
  Alejandro de Janon, Pranitha Kaza, Kaede Yoshida, SooJung Lee, Deborah DeRyckere
  Iscience. 2026-01-16
• Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.
  Denis Ohlstrom, Mojtaba Bakhtiari, Hope Mumme, Marina Michaud, Alejandro De Janon Gutierrez
  Leukemia. 2025-11-01
• Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.
  Denis Ohlstrom, Mojtaba Bakhtiari, Hope Mumme, Marina Michaud, Alejandro De Janon Gutierrez
  Leukemia. 2025-11-01

Journal Articles

• The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer  
  Graham DK, DeRyckere D, Davies KD, and HS Earp, Nat Rev Cancer, 1/1/2014
• Epigenetic reprogramming to reverse chemoresistance in childhood acute lymphoblastic leukemia  
  Newton TP, Cummings CT, Graham DK, and KM Bernt, International Journal of Hematologic Oncology, 1/1/2014
• mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop  
  Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, and LE Heasley, Oncogenesis, 1/25/2013

Books/Book Chapters

• Current Pediatric Diagnosis and Treatment 
  Chapter: Neoplastic disease 
  Page 885 - 916Maloney K, Greffe , Foreman NK, Porter CC, Graham DK, Sawczyn K, Giller RH, Quinones RR, and AK KeatingEditors: Hay WW, Levin MJ, Sondheimer JM, and RR Deterding.McGraw-Hill, New York, NYEdition 18th,2007
• Current Pediatric Diagnosis and Treatment 
  Chapter: Hematopoietic stem cell transplantation 
  Page 916 - 918Graham DK, Giller RH, and RR QuinonesEditors: Hay WW, Groothuis JR, Hayward AR, and MJ Levin.McGraw-Hill, New York, NYEdition 16th,2003
• Peripheral Blood Stem Cells 
  Chapter: Embryonic stem cells: research and clinical potentials 
  Page 65 - 83Snodgrass HR, Graham DK, Stanford WL, and LL LicatoEditors: Smith DM, Sacher RA, and LC Jefferies.American Association of Blood Banks, Bethesda, MD1993

Abstracts/Posters

• Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia
  DeRyckere D, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia
  Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, and DK Graham, American Society of Hematology 56th Annual Meeting; Blood, San Francisco, CA, 1/1/2014
• UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft ...
  DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, and DK Graham, American Society of Hematology 56th Annual Meeting; Blood, San Francisco, CA, 1/1/2014

Lectures

• Targeted inhibition of MerTK as novel cancer therapy 
  Madison, WI - 1/18/2015
• Transitioning MerTK Inhibitors Into the Clinic as Novel Cancer Therapy 
  1/15/2015
• Development of dual Mer/FLT3 inhibitors 
  Boulder, CO - 1/12/2015

Other

• The MERTK signaling pathway in cancer 
  Hill AA, Carrico JA, DeRyckere D, and DK Graham, eLS. John Wiley & Sons, Ltd
  1/1/2015